Absci (ABSI) PE Ratio: History & Chart

Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.

The P/E ratio is N/A as of 2026-10-06T21:40:32.034Z.

Stored calculation inputs

Calculation as of: 2026-10-06T21:40:32.034Z.

Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.

Quote price: 10.27
Unrounded diluted TTM EPS · period ending 2026-06-30: -0.8

FMP input reference: 6c856baf2af26ca9326fa79b8c43a58fbb1378fdf70f4049426595b89831cd0b

Forward PE Ratio|PEG Ratio|P/B Ratio|EPS|All Metrics

ABSI PE Ratio Metrics

PE RATIO

N/A

ABSI Competitors' PE Ratio

ABSI

Absci Corporation

Current

Market Cap

$1.74B

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

XERS

Xeris Biopharma Holdings, Inc.

vs ABSI

Market Cap

$1.74B

PE Ratio

N/A

TTM Avg

112.77

3Y Avg

112.77

5Y Avg

112.77

NVCR

Novocure Ltd

vs ABSI

Market Cap

$1.74B

PE Ratio

N/A

TTM Avg

1067.41

3Y Avg

1002.04

5Y Avg

1002.04

ALHC

Alignment Healthcare, Inc.

vs ABSI

Market Cap

$1.74B

PE Ratio

44.86

TTM Avg

147.35

3Y Avg

147.35

5Y Avg

147.35

NTLA

Intellia Therapeutics, Inc.

vs ABSI

Market Cap

$1.73B

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

SGRY

Surgery Partners, Inc.

vs ABSI

Market Cap

$1.75B

PE Ratio

N/A

TTM Avg

7340.14

3Y Avg

7340.14

5Y Avg

7340.14

PSNL

Personalis, Inc.

vs ABSI

Market Cap

$1.71B

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

GENB

Generate Biomedicines, Inc.

vs ABSI

Market Cap

$1.77B

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

XRAY

DENTSPLY SIRONA Inc.

vs ABSI

Market Cap

$1.71B

PE Ratio

N/A

TTM Avg

23.72

3Y Avg

50.63

5Y Avg

57.39

ZBIO

Zenas BioPharma, Inc.

vs ABSI

Market Cap

$1.70B

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	PE RATIO	TTM	3Y	5Y
Absci Corporation (ABSI)	$1.74B	N/A	N/A	N/A	N/A
Xeris Biopharma Holdings, Inc. (XERS)vs ›	$1.74B	N/A	112.77	112.77	112.77
Novocure Ltd (NVCR)vs ›	$1.74B	N/A	1067.41	1002.04	1002.04
Alignment Healthcare, Inc. (ALHC)vs ›	$1.74B	44.86	147.35	147.35	147.35
Intellia Therapeutics, Inc. (NTLA)vs ›	$1.73B	N/A	N/A	N/A	N/A
Surgery Partners, Inc. (SGRY)vs ›	$1.75B	N/A	7340.14	7340.14	7340.14
Personalis, Inc. (PSNL)vs ›	$1.71B	N/A	N/A	N/A	N/A
Generate Biomedicines, Inc. (GENB)vs ›	$1.77B	N/A	N/A	N/A	N/A
DENTSPLY SIRONA Inc. (XRAY)vs ›	$1.71B	N/A	23.72	50.63	57.39
Zenas BioPharma, Inc. (ZBIO)vs ›	$1.70B	N/A	N/A	N/A	N/A

P/E Comparison

Trailing P/E

N/A

Forward P/E

N/A

Forward P/E Calculation

View All Analyst Estimates

Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.

Calculation:

Current Price

$10.27

÷

Forward EPS (Est.)

$-0.80

=

Forward P/E

N/A

Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.

PE Ratio Formula & Definition

PE Ratio = Share Price / Diluted EPS (TTM)

The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

See the Lowest P/E Ratio Stocks ranking →

PE Ratio: N/A

ABSI PE Ratio Metrics

ABSI Competitors' PE Ratio

P/E Comparison

Forward P/E Calculation

PE Ratio Formula & Definition

Related Metrics